BICO Group AB 559050-5052 (NASDAQ STOCKHOLM: BICO)

BICO is the future of life-saving treatments. We are reducing the organ shortage and speeding up drug development by providing accessible life science solutions that combine biology and technology.

JULY – SEPTEMBER 2022
(COMPARED WITH JULY – SEPTEMBER 2021)
Net sales amounted to MSEK 550.6 (315.6), which corresponds to an increase of 74% (292) compared to the corresponding period previous year.

Organic growth for the period amounted to 28% (59). Organic growth excluding currency effects for the period was 12%.
EBITDA amounted to MSEK 1.8 (-33.8), corresponding to a margin of 0.3% (-10.7).

Adjusted EBITDA amounted to MSEK 18.1 (-16.0), corresponding to a margin of 3.3% (-5.1)

Net profit/loss for the period amounted to MSEK 66.5 (-105.0), corresponding to earnings per share before and after dilution of SEK 1.04 (-1.82).

The gross margin amounted to 76.5% (73.1). The gross margin structure in the acquired companies 2021 varies depending on the product mix.

JANUARY – SEPTEMBER 2022
(COMPARED WITH JANUARY – SEPTEMBER 2021)
Net sales amounted to MSEK 1.565.4 (738.2), which corresponds to an increase of 112% (365) compared to the corresponding period previous year.

Organic growth for the period amounted to 24% (69). Organic growth excluding currency effects for the period was 10%.
EBITDA amounted to MSEK -80.6 (-58.1), corresponding to margin of -5.0% (-7.9).

Adjusted EBITDA amounted to MSEK 35.3 (-7.3), corresponding to a margin of 2.3% (-1.0).

Net profit/loss for the period amounted to MSEK 66.1 (-203.3), corresponding to earnings per share before and after dilution of SEK 1.04 (-3.62).

“Given the change in the macroeconomic environment, we have a firm focus on profitability and cash flow.”
Erik Gatenholm/ President & CEO, BICO Group AB

Q3 KEY TAKEAWAYS
· Strong product demand and high sales
· Focus on improving profitability and cash flow
· Focus on operational efficiency and acquisitions synergies
· Cost reduction program launched

INVITATION TO PRESENTATION:
Join us for a combined presentation audiocast and telephone conference with the opportunity to ask questions at 09:00 CEST today on November 9, 2022, with President & CEO Erik Gatenholm and Interim CFO Mikael Engblom. The presentation audiocast will be accessible via the following link:

Audiocast, at 09:00 am CEST:
https://ir.financialhearings.com/bico-q3-2022

To participate via telephone, please call any of the following numbers:
SE: +46 8 505 16 386
UK: +44 203 198 48 84
US: +1 412 317 6300

Pin: 6705948#

The presentation will also be available on the company’s website:
 https://bico.com/investors/financials/financial-reports-and-presentations/